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The Editorial on the Research Topic
Molecular Mechanisms Protecting against Tissue Injury
In response to tissue injury acute inflammatory reactions occur that aim to restore homeostasis
(Medzhitov, 2008). However, hampered resolution of inflammation can result in chronic
inflammation and/or pathologic wound repair (Nathan and Ding, 2010). These conditions can
result from excessive oxidative and inflammatory and/or overwhelmed adaptive response systems.
They may also be triggered by a variety of other conditions including diabetes, infections, or aging.
Targeted up-regulation of cytoprotective systems may be a therapeutic approach to ameliorate
exacerbation of injury and prevent pathologic wound repair, fibrosis and/or cancer (Nathan, 2002).
Such protective systems include various anti-oxidant, anti-inflammatory, anti-apoptotic molecules
and also transporters or channels. In this Frontiers research topic various concepts how specific
mechanisms can determine tissue damage or protection and their therapeutic potential in a number
of pathological conditions and diseases are discussed.
Tissue damage control is important at different levels to maintain homeostasis of cells, tissues
and whole organisms. For example, when immunological reactions are primarily directed against
the cause of tissue damage (e.g., pathogenic microbes), excessive collateral damage may occur.
In such cases, avoiding additional tissue damage would be more important than elimination of
the disease-triggering stimulus (Soares, 2014; Soares et al., 2014). Severe tissue injury can lead to
chronic inflammation, fibrosis, disturbed developmental changes and cancer (Reuter et al., 2010),
which underscores the need to prevent tissue damage and/or to promote regeneration.
The coordinate immunological functions to maintain tissue homeostasis is orchestrated by a
selected group of immune cells (Shalapour and Karin, 2015) such as dendritic cells (Mirzaee et al.)
and regulatory T-cells (Lei et al.). Targeted modulation of these regulators may thus give control
on the decisive machinery that determines immunity, inflammation, tissue remodeling, and cancer
(Sutmuller et al., 2007). Infusion of regulatory T-cells facilitates tissue regeneration by preventing
undesired immunological activity and by controlling resident non-immune tissue cells and forms
an alternative strategy to dampen tissue injury (Lei et al.).
Mizumura and colleagues describe how autophagy may promote tissue damage or repair and
novel developments in its regulation (Mizumura et al.). In particular, the role of selective autophagy
in a variety of human diseases and the therapeutic potential of this system is discussed.
Surgery and other types of traumatic injury not only cause inflammatory injury, fibrosis, and
scar formation (Brouwer et al., 2015), but are associated with the release of free heme (Wagener
et al., 2003a). Heme is the prosthetic group of a number of physiologically important hemoproteins
(e.g., hemoglobin, cytochromes or cyclooxygenase). However, when heme is not embedded in
apoproteins which occurs in pathophysiological situations such as hemolysis or tissue injury, it
can mediate or fuel oxidative, inflammatory, and fibrotic insults and may act as a danger signal
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(Nath et al., 1992; Wagener et al., 2003a,b; Lundvig et al.; Wegiel
et al., 2015). High levels of free heme may contribute to or
exacerbate tissue injury for example by promoting adhesion
molecule expression and leukocyte recruitment (Wagener et al.,
2001, 2003a; Belcher et al., 2010; Larsen et al., 2010; Gozzelino
and Soares, 2011; Zenclussen et al., 2011). Therefore, protective
mechanisms against free heme such as neutralization by either
intra- or extra-cellular heme-binding proteins (e.g., hemopexin)
or enzymatic heme-degradation by heme oxygenases (HOs) may
have important protective functions (Immenschuh et al., 1995;
Wagener et al., 2003b, 2013; Kartikasari et al., 2009).
Previously, it has been shown that exposure to small injurious
stress stimuli is protective against a follow-up stronger stress.
This so-called preconditioning may thus have beneficial effects to
protect tissues against injury by promoting cytoprotective signals
(Murry et al., 1986). It has been shown that this tissue protection
is associated with the induction of cytoprotective genes, such as
HO-1, A20, hemopexin, and biliverdin reductase (BVR) (Keyse
and Tyrrell, 1989; Hancock et al., 1998).
A major protection system is made up by the HO-
1/BVR module. HO is the rate-limiting enzyme of heme
degradation, which produces carbon monoxide, iron, and
biliverdin, which is converted into bilirubin by BVR. Induction
of these cytoprotective proteins has been shown to prolong
graft survival after solid organ transplantation by skewing
toward a more tolerant immune system (Wagener et al.,
2003b). Moreover, HO-activity attenuates the expression of
pro-inflammatory cytokines and vascular adhesion molecules,
promoting resolution of inflammation (Wagener et al., 2001; Di
Francesco et al., 2009). Similar to transplanted organs, tumors are
immunologically different to healthy, non-transformed tissues,
suggesting that they may also benefit from these cytoprotective
enzymes. Likewise, fetuses in the uterus are expressing maternal
and paternal proteins, and are thus comparable with an
allotransplant. In this topic, it is described how probing
antioxidant genes such as HO and BVR could form novel targets
for preventing pathological pregnancies (Ozen et al.) and cancer
(Gibbs et al.), respectively. Induction of HO activity or exposure
to its effector molecules protect against pathological pregnancies,
whereas reduced HO-activity disturbs normal pregnancy (Ozen
et al.).
BVR interacts with various protein kinases and is involved
in a complex system of regulatory pathways. The effects of
BVR not only have an important impact on the pathogenesis
of cancer, but targeting of this enzyme may ultimately afford
the development of novel therapies in cancer (Gibbs et al.).
Although, cytoprotective systems such as HO-1/BVR are
generally considered to be beneficial, they may be harmful under
particular circumstances. For example, it has been demonstrated
that HO-1 is involved in the pathogenesis of cancer, because
it can protect tumor cells against immune surveillance (Was
et al., 2010). Moreover, HO-1 has recently been suggested to be
involved in transforming obesity to diabetes (Jais et al., 2014).
Therefore, the effects of such cytoprotective systems appear to
be critically dependent on cell-type and tissue-context-specific
mechanisms.
Another review in this Frontiers topic by Horbach et al.
addresses the role of the nuclear factors upstream stimulatory
factor (USFs)-1 and -2 in the context of carcinogenesis and tissue
injury. USFs have primarily been considered to be involved in
the regulation of metabolism, but have also been shown to be
intimately associated with tissue protection and the pathogenesis
of cancer. Here, the complexity of USF-1 and -2 regulation by
various kinases in carcinogenesis is discussed.
Finally, a feasible approach to afford targeted protection in
various pathological conditions is to trigger defined protective
pathways with safe plant components. For example, induction
of anti-inflammatory pathways with herbal compounds
and antioxidants suppressed expression of proinflammatory
cytokines in human peripheral blood mononuclear cells
(Spatuzza et al.), adipose cells (Zagotta et al.), and dendritic
cells (Mirzaee et al.). Interestingly, many dietary and natural
compounds have been demonstrated to activate nuclear factor
erythroid 2-related factor (Nrf2), which in turn induces a
number of protective enzymes, such as HO-1, and promote
therapeutic effects in cardiovascular diseases (Barbagallo et al.,
2013). However, when translating novel protective strategies
from the bench to the clinic possible differences in experimental
outcome between animal models, cell lines, healthy controls and
patients need to be considered (Dorresteijn et al., 2015).
Better insights into the observed differences between pre-
conditioning and post-conditioning in relation to tissue repair
could further deepen our understanding of these regulatory
pathways. It appears likely that learning more about the
molecular mechanisms protecting against tissue damage will
enable the development of better strategies to prevent or
ameliorate wound repair and promote healthy aging.
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